Accord Healthcare: The Evolution of Generics

Accord Health care, located in Durham, North Carolina, is an emerging provider of generic pharmaceuticals in the U.S. Although we are a newer commercial supplier, our parent company, Intas Pharmaceuticals, has been a pioneer in the industry since 1976. You’ve probably seen us in the news lately. We codeveloped several of the first biosimilar filings in the U.S., and that was just a start. We first began building our specialty and biotech manufacturing plants in 2001 and were also the first company of Indian origin to gain approval and launch a biosimilar in Europe.

In our early days, we provided R&D and commercial manufacturing for partners in the regulated markets. Over the past decade, we have built the formulation expertise and manufacturing capacity to directly supply a vast portfolio of generic oral solids and injectables, oncology injectables, specialty injectables and biosimilars.

Solid, Sustainable Growth

Since 2009, we have been delivering reliable supply and quality excellence in products sold in the U.S. under the Accord label. Our solid record of maintaining high quality standards has set us apart in the industry. Our goals toward growth continue to be aggressive and have always been matched by our desire to exceed our customers’ expectations.

Quarter over quarter, we consistently accomplish doubledigit growth across all the metrics: in dollar sales, scripts filled and number of units sold. We have accomplished this while undergoing multiple plant expansions across all of our manufacturing sites.

Accord is integrated in Active Pharmaceutical Ingredients, as well as Clinical Research work through our subsidiary, Lambda Therapeutic Research. We are proud of our strong global presence, currently selling in over 70 countries worldwide.

Today and Tomorrow

Accord’s current product offerings and pipeline demonstrate our commitment to meeting the needs of health care professionals and patients alike. We currently have approval for 50 ANDAs and are selling 165 dosing presentations. We have 79 ANDAs pending at the FDA and over 100 products in active development. Our pipeline spans a full range of dosage forms: orals, topicals, transdermal patches, liquid, lyophilized and peptide injectables. And due to our broad catalog of biosimilar products in the combined Indian and European markets (where we are currently selling 9 biosimilars) we also have a robust biosimilar pipeline for the U.S.

At Accord, we are committed to Improving Lives through Innovation.

For more information, visit http://accord-healthcare.com.